GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (NAS:ABVX) » Definitions » ROE % Adjusted to Book Value

ABVX (Abivax) ROE % Adjusted to Book Value : -58.23% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Abivax ROE % Adjusted to Book Value?

Abivax's ROE % for the quarter that ended in Dec. 2023 was -183.43%. Abivax's PB Ratio for the quarter that ended in Dec. 2023 was 3.15. Abivax's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -58.23%.


Abivax ROE % Adjusted to Book Value Historical Data

The historical data trend for Abivax's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax ROE % Adjusted to Book Value Chart

Abivax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -46.21

Abivax Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -58.23

Competitive Comparison of Abivax's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Abivax's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abivax's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Abivax's ROE % Adjusted to Book Value falls into.



Abivax ROE % Adjusted to Book Value Calculation

Abivax's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-145.56% / 3.15
=-46.21%

Abivax's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-183.43% / 3.15
=-58.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abivax ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Abivax's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Abivax Business Description

Industry
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.